Head to Head Contrast: Nemaura Medical (NASDAQ:NMRD) and CVRx (NASDAQ:CVRX)

Nemaura Medical (NASDAQ:NMRD) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Volatility and Risk

Nemaura Medical has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, CVRx has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Earnings & Valuation

This table compares Nemaura Medical and CVRx”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$3,017.00	1.34	-$14.14 million	($0.39)	0.00
CVRx	$52.87 million	2.88	-$59.97 million	($2.18)	-2.67

Nemaura Medical has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Nemaura Medical and CVRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	0	0	0.00
CVRx	1	0	6	0	2.71

CVRx has a consensus price target of $14.50, indicating a potential upside of 148.71%. Given CVRx’s stronger consensus rating and higher probable upside, analysts clearly believe CVRx is more favorable than Nemaura Medical.

Profitability

This table compares Nemaura Medical and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	N/A
CVRx	-97.49%	-79.04%	-42.37%

Insider & Institutional Ownership

4.4% of Nemaura Medical shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 40.4% of Nemaura Medical shares are held by company insiders. Comparatively, 13.9% of CVRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.